Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Synd... ( CARSON CITY Nev. Dec. 21 2011 /- ...)

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study

Date:12/21/2011

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. (OTCBB: DCMG) announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel. The randomized, double-masked clinical trial will include 231 patients who will be randomized to receive 2 doses of CF101 and Placebo, for a period of 24 weeks. The primary efficacy endpoint will be complete clearing of corneal staining.

The population suffering from Dry Eye Syndrome is estimated at 49 million people in the seven major markets and is characterized by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial disease. People with Dry Eye Syndrome experience constant ocular discomfort and a decrease in visual function; in severe cases, Dry Eye Syndrome may result in deterioration of vision.

Dr. Pnina Fishman, the Company's interim CEO stated, "We are very pleased with the initiation of enrollment to the Dry Eye Syndrome phase 3 study. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral drug for the treatment of Dry Eye Syndrome."

In addition, the Company announces today that by action of the Board of Directors and the shareholders, it has changed its name to OphthaliX Inc.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications including Dry Eye Syndrome (Phase 3), Glaucoma (Phase 2) and Uveitis. CF101 is also developed for the trea
'/>"/>

SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
2. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
5. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. Cellectar Expands Clinical Management Team
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Micromet Announces Changes in Management Team

Post Your Comments:

(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...

(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012 Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...

(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...

Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2 Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4

[0] Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting [0] Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream [0] Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...

... Joint Venture Between Bristol-Myers Squibb, Company ... in HIV Treatment -, PRINCETON, N.J. and ... Company (NYSE: BMY ) and Gilead Sciences, ... Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir ...

New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...

(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...

(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...

(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...

(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...

Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2 Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2 Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4 Health News:Cleft lip/palate cause much more than cosmetic problems 2

[0] Landmark textbook on health care and the US legal system released [0] Aggregating instead of stabilizing: New insights into the mechanisms of heart disease [0] Viral infections in infancy are not associated with wheezing symptoms in later childhood [0] Mayo Clinic urologists present findings at American Urological Association Annual Meeting [0] Cleft lip/palate cause much more than cosmetic problems

... Inc. (NYSE: CSV ) today announced results for the first quarter ended March 31, 2009. Highlights from continuing operations for ... in millions, except per share amounts) , , ... Q1, ... Change, ...

... Inc.,s parent company, Team Finance LLC (the "Company"), today announced ... less provision for uncollectibles ("revenue less provision") in the first ... million in the first quarter of 2008. Same contract ... million from $305.5 million in the same period a year ...

... of these meds with their doctor, cardiac group says ... takes the clot-preventing drug Plavix after receiving a stent ... medications called proton pump inhibitors (PPIs), if possible, a ... blockbuster acid reflux medications such as Nexium, Prevacid and ...

... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...

... age of those hospitalized in U.S. is 15, CDC says ... majority of U.S. cases continue to be mild, those who ... atypically young, health officials said Wednesday. , In fact, the ... which is younger than occurs in regular seasonal flu, U.S. ...

... The following was released today by Americans for ... National Institute for Occupational Safety and Health (NIOSH) ... dangerous levels of secondhand smoke at work. NIOSH recommends ... casinos is safe for workers to breathe. In 2005, ...

Carriage Services Announces First Quarter 2009 Results Team Finance LLC Announces First Quarter 2009 Results Plavix, Heartburn Drugs May Be Risky Combination Regence Foundation Grants $390,000 to Improve Health Care Safety Net Younger Age of Severe Swine Flu Cases Worries Experts No Safe Bets for Casino Workers: NIOSH Study Shows Casino Workers Face Toxic Conditions

Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...

Stylet - Infant Stainless Steel, Flexible, Non-Sterile, Latex Free, With stop, Suitable for tubes 2.0 mm I.D. or larger....

... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...

All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....

Medicine Products:

Slick® Disposable Endotracheal Stylet 6 Fr Endotracheal Tube Stylet - Infant Lighted Pediatric Stylet - Sterile Blue Line® Intubation Stylet 5.0 mm 7.0 mm

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Synd...( CARSON CITY Nev. Dec. 21 2011 /- ...),Health